FINNENCE ▪ THE WIRE FILE
THE WIRE · № 84818
SEC Filing■ Unclear/unknown
NKE filed 4 on 2026-10-16
KINDSEC Filing
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A Form 4 reports insider transactions; direction depends on whether shares were bought or sold, which the text does not state.
Insider activity noted but direction unknown
CATALYST TO WATCH
Details of the transaction in the full filing
MAIN RISK
Could reflect insider selling if disclosed as such
FULL DISPATCH
NKE (CIK 0001371578) filed a 4 on 2026-10-16.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTNike · NKE
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects — Onconic Therapeutics Inc.2026-10-15 12:00 UTC
New Phase 3 trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects — Onconic Therapeutics Inc.2026-10-15 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer — Hinova Pharmaceuticals Inc.2026-10-15 12:00 UTC
New Phase 3 trial: A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer — Hinova Pharmaceuticals Inc.2026-10-15 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants — Regeneron Pharmaceuticals2026-10-15 12:00 UTC
New Phase 3 trial: A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants — Regeneron Pharmaceuticals2026-10-15 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity — Pfizer2026-10-15 12:00 UTC
New Phase 3 trial: A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity — Pfizer2026-10-15 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With Hemophilia — Shanghai RAAS Blood Products Co., Ltd.2026-10-15 12:00 UTC
New Phase 3 trial: A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With Hemophilia — Shanghai RAAS Blood Products Co., Ltd.2026-10-15 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.